Multi-Omics Investigation of Innate Navitoclax Resistance in Triple-Negative Breast Cancer Cells

摘要

Triple negative breast cancer is a disease with limited treatment options and the poorest outcome across all breast cancer subtypes, thus the need for new effective therapies is high. We recently found that navitoclax displays synergistic anti-proliferative and apoptotic activities with other drugs in treatment of triple negative breast cancer cells, but the resistance to treatment is still a limiting factor. Therefore, we investigated the effects of navitoclax treatment on the transcriptome, genome and epigenome in vitro to better understand the process of developing resistance. We discovered and validated a list of multiple, previously unknown markers of drug resistance that can help in patient selection in future clinical trials involving navitoclax.